UNSPSC 51172335: Gadopenamide

This classification denotes a gadolinium-chelate with the molecular formula C22H34N5O10.Gd, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VC7M3XD17L, chemically known as (n,n-bis(2-((carboxymethyl)((morpholinocarbonyl)methyl)amino)ethyl)glycinato(3-))gadolinium but more generally known as gadopenamide, which bears US NIH Compound Identifier 3034033. European Medicines Agency schedules Gadopenamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07863MIG.

UNSPSC 51172335 Gadopenamide, a Commodity code, nominally identifies a specific diagnostic contrast agent, but recent state and local solicitations tagged under this code show little activity directly aligned with that product. The recent opportunities span offender drug testing services, therapeutic pharmacy initiatives, and multi-source generic pharmaceutical distribution — none of which center on gadopenamide procurement. State and local governments use this code inconsistently or rarely for its nominal scope. Issuing bodies appearing in the recent record include a county criminal justice department (Collin County Community Supervision and Corrections Department in Texas), a state health and human services commission (Texas HHS Commission), and a multistate cooperative purchasing alliance (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, administered by Minnesota Department of Administration). The diversity of issuing bodies and the mismatch between the code's nominal product and the actual work solicited suggest that gadopenamide itself sees minimal or no recent procurement activity at the state and local level.

Geographic activity appears concentrated in Texas and Minnesota based on recent postings. Collin County (Texas) issued an RFP for offender specimen collection and drug testing services with a response deadline of July 23, 2026 and estimated annual value of $600,000 for a two-year term with optional renewals. Texas HHS Commission posted a Request for Information on therapeutic pharmacy initiatives with a response deadline of April 3, 2026, designed to gather vendor capabilities before issuing a formal RFP. MMCAP, serving Minnesota and participating jurisdictions including Oregon, issued an RFP for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026. The code shows no clear recent demand signal for gadopenamide as a standalone procurement item; business development teams should verify whether activity under this code relates to their service offering before investing pursuit resources.